Plasma therapy in corona patients(Severe COVID-19).
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J128- Other viral pneumonia
- Registration Number
- CTRI/2020/06/026123
- Lead Sponsor
- Dr Sushant Meshram
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Hospitalized COVID-19 patients, Fever Cough breathlessness plus one or more of the following respiratory rate more than 30 per minutes, O2 saturation less than 90%, PaO2 by FiO2 less than 300. Patients with Comorbidities Viz.DM,COPD,HTN,Asthma included.
Exclusion Criteria
Pregnant and Breast Feeding Females, Critically ill patients viz. Severe ARDS,Sepsis,Septic shock MODS,Coronary artery disease,arrhythmia Heart Failure.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients showing at least 2 points clinical improvement on WHO ordinal scale at 28 days post randomization. <br/ ><br>All cause mortality at 28 daysTimepoint: 28 days
- Secondary Outcome Measures
Name Time Method Time to clinical improvement. <br/ ><br>Length of hospital stay. <br/ ><br>Change in SOFA score. <br/ ><br>Duration of oxygen support. <br/ ><br>Duration of respiratory support required. <br/ ><br>Levels of biomarkers CRP Ferritin,D Dimer pre and posttransfusion. <br/ ><br>Radiological improvement. <br/ ><br>Timepoint: 28 days